Selank
Heptapeptide derived from Tuftsin. Modulates BDNF expression and catecholamine metabolism. Acts as a stable anxiolytic via allosteric regulation of GABA-A.
- Reduction of generalised anxiety
- Improved mental clarity (without sedation)
- Modulation of the immune system
- Emotional stabilityReduction of generalised anxiety
- Emotional stability
- May induce mild drowsiness at high doses.
Selank is a synthetic peptide analogue of tuftsin, developed by the Russian Institute of Molecular Genetics, with anxiolytic and nootropic properties that do not cause sedation or addiction.
READ MORE
What it is (in plain language)
- It's a 'smart calmer'. It helps lower anxiety and stress, but instead of making you sleepy, it improves focus and memory. It regulates serotonin and dopamine levels, helping the brain to remain resilient under extreme emotional pressure.
Why do you appear online so much
- It's a favourite of high-performance professionals who suffer from anxiety but need to maintain mental clarity. It's often used via nasal spray because of its speed of action and because it doesn't have the heavy side effects of benzodiazepines (such as Xanax).
How it is framed today (pragmatic view)
- 1) Evidence: Established clinical use in Russia for decades for anxiety disorders. 2) Objective: Reduction of stress, anxiety and improvement of learning. 3) Risk: Very safe, with no record of dependence or withdrawal syndromes.
How to use this form
- Explore the 'Handling Notes' section to learn about the storage of the nasal spray peptide.
- Quick profile (curated by Subject 157)
- Class: Nootropic
- Status: Verified
- Use case: Nootropic
- Route: Nasal
- Tags: Nasal|Injectable|Anxiety
- Half-life: ~24 Hours
- Start: Fast
- Duration: ~24 hours
- Mechanism (high level)
Heptapeptide derived from Tuftsin. Modulates BDNF expression and catecholamine metabolism. Acts as a stable anxiolytic via allosteric regulation of GABA-A.
- Evidence (what the literature covers)
RESEARCH RANGE (Russian, Non-prescriptive):
Common doses of 300mcg to 1mg.
Level of Evidence: B (Clinical use in Russia).
- Safety and harm-reduction (non-prescriptive)
Risks: May induce mild drowsiness in high doses.
Interactions: Unknown.
- References (anchors)
- Zozulya, A. A. (2017) - Selank and immunomodulatory effects - https://doi.org/10.1155/2017/5091027 | PubMed:28589139
- Kolomin, T. (2019) - Selank gene expression in the brain - https://doi.org/10.1007/s10517-019-04588-9 | PubMed:31541334
Note: Educational/research content. Does not constitute medical advice, diagnosis or prescription.
